abstract |
The present invention has been found that a compound that acts as an agonist on the ORL-1 receptor acts as a non-phototuning factor to advance the phase of circadian rhythm, such as circadian rhythm sleep disorder Provided are novel therapeutic agents for sleep disorders, in particular, prophylactic and / or therapeutic agents for sleep disorders containing an ORL-1 receptor agonist, and novel compounds useful as such prophylactic and / or therapeutic agents. |